Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Schizophrenia affects 1% globally, requiring lifelong therapy.
• Dopamine pathway hyperfunction has been the dominant hypothesis, but treatments offer limited efficacy.
• PCP's ability to mimic schizophrenia symptoms supports alternative theories.

Purpose of the Study:

• To review progress validating the NMDA receptor hypofunction hypothesis of schizophrenia in preclinical models.
• To discuss the NMDA receptor as a target for novel antipsychotic drug development.
• To explore therapeutic strategies modulating NMDA receptor currents.

Main Methods:

• Review of preclinical research on NMDA receptor function in schizophrenia models.
• Discussion of agents directly modulating NMDA receptor sites (e.g., glycine co-agonist site).
• Exploration of indirect modulation via G-protein coupled receptors (GPCRs) like mGluR5.

Main Results:

• NMDA receptor hypofunction is a viable alternative hypothesis for schizophrenia.
• Agents potentiating NMDA receptor currents may ameliorate schizophrenia symptoms.
• In vivo validation progress with GlyT1 inhibitors and mGluR5 positive allosteric modulators is discussed.

Conclusions:

• The NMDA receptor is an emerging target for novel antipsychotic agents.
• Modulating NMDA receptor currents offers a promising therapeutic avenue.
• Further research into various NMDA receptor modulation sites is warranted.